We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA is calling out a Taiwanese drugmaker for a slew of GMP violations circling its quality control unit's written procedures, rendering its products adulterated. Read More
Citing the nation’s opioid epidemic, the two top members of the Senate Special Committee on Aging have written to five different drugmakers inquiring about their efforts to improve access to opioid rescue drug naloxone. Read More
A district court judge has spared Gilead from paying a hefty sum in damages to Merck over a HCV patent dispute, overturning a March San Jose federal jury ruling. Read More
British authorities have warned Reckitt Benckiser that it may have to submit all advertising for vetting if it makes another false efficacy claim for its laxative Senokot. Read More
Allergan has clinched FDA approval for its hypertension treatment Byvalson, the first fixed-dose combination of a beta blocker and angiotensin II receptor blocker in the U.S. Read More
A second FDA complete response letter to Adamis Pharmaceuticals for its acute anaphylaxis candidate requests an extension of its human factors and reliability studies. Read More